Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery

This study has been completed.
Information provided by:
Allergan Identifier:
First received: August 23, 2007
Last updated: September 29, 2009
Last verified: August 2009

This is a 16 day study to evaluate the safety and efficacy of ketorolac eye drops for the treatment of inflammation and pain associated with cataract surgery

Condition Intervention Phase
Cataract Extraction
Drug: ketorolac eye drops
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Allergan:

Primary Outcome Measures:
  • Resolution of Post Operative Inflammation [ Time Frame: Day 14 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Ocular Pain [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Mean Pupil Area [ Time Frame: Day 0 ] [ Designated as safety issue: No ]

Enrollment: 263
Study Start Date: October 2007
Study Completion Date: March 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: ketorolac eye drops

1 drop twice daily day preop and Days 1-14, and 6 doses on surgery day


Placebo Comparator: 2 Drug: ketorolac eye drops

1 drop twice daily day preop and Days 1-14, and 6 doses on surgery day



Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients undergoing cataract surgery

Exclusion Criteria:

  • Uncontrolled ocular disease in cataract surgery eye
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00521456

United States, California
San Diego, California, United States
Sponsors and Collaborators
Study Director: Medical Director Allergan
  More Information

Additional Information:
No publications provided by Allergan

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Therapeutic Area Head, Allergan, Inc. Identifier: NCT00521456     History of Changes
Other Study ID Numbers: 191578-006
Study First Received: August 23, 2007
Results First Received: August 19, 2009
Last Updated: September 29, 2009
Health Authority: United States: Food and Drug Administration processed this record on March 03, 2015